CRNX — Crinetics Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $3.35bn
- $2.79bn
- $4.01m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.19 | 0.071 | 1.08 | 4.74 | 4.01 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 55 | 75 | 109 | 173 | 227 |
Operating Profit | -53.8 | -75 | -108 | -168 | -223 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -50.4 | -73.8 | -108 | -163 | -209 |
Net Income After Taxes | -50.4 | -73.8 | -108 | -163 | -209 |
Equity in Affiliates | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -50.4 | -73.8 | -108 | -164 | -215 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -50.4 | -73.8 | -108 | -164 | -215 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.09 | -2.42 | -2.8 | -3.15 | -3.69 |